AKTX logo

Akari Therapeutics (AKTX) Company Overview

Profile

Full Name:

Akari Therapeutics, Plc

Sector:

Healthcare

Industry:

Biotechnology

Country:

United States

IPO:

January 6, 2014

Indexes:

Not included

Description:

Akari Therapeutics is a biotechnology company focused on developing innovative treatments for rare and serious diseases. They specialize in therapies that target the immune system, aiming to improve the lives of patients with conditions like autoimmune disorders and other inflammatory diseases.

Events Calendar

Earnings

Next earnings date:

Apr 1, 2025

Recent quarterly earnings:

Aug 19, 2024

Recent annual earnings:

Apr 1, 2024
Dividend

Next ex-dividend date:

N/A

Recent ex-dividend date:

N/A
Splits

Next split:

N/A

Recent split:

Aug 21, 2023

Analyst ratings

Recent major analysts updates

Dec 5, 22 HC Wainwright & Co.
Buy
Nov 1, 22 Alliance Global Partners
Buy
Mar 13, 20 B. Riley Securities
Buy
Mar 13, 20 B. Riley FBR
Buy
May 5, 18 B. Riley FBR
Neutral
Mar 29, 18 Canaccord Genuity
Buy
Feb 8, 18 B. Riley Securities
Neutral
Feb 8, 18 B. Riley FBR
Neutral
Sep 22, 17 William Blair
Outperform
May 31, 17 Chardan Capital
Neutral

Market Data

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Price

Market cap

Technical

Dividend

Profitability

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Revenue

Profit

EPS

ROA & ROE

EBIT & EBITDA

Valuation

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

PE Ratio

PB Ratio

PS Ratio

Enterprise value

EV/EBITDA

Financial Health

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Liquidity

Leverage

Risk & Stability

Balance Sheet

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Assets

Equity

Liabilities

Debt

Expenses

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Cash Flow

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Cashflow Activities

Free CashFlow

CAPEX

Institutional Ownership

FAQ

  • What is the ticker symbol for Akari Therapeutics?
  • Does Akari Therapeutics pay dividends?
  • What sector is Akari Therapeutics in?
  • What industry is Akari Therapeutics in?
  • What country is Akari Therapeutics based in?
  • When did Akari Therapeutics go public?
  • Is Akari Therapeutics in the S&P 500?
  • Is Akari Therapeutics in the NASDAQ 100?
  • Is Akari Therapeutics in the Dow Jones?
  • When was Akari Therapeutics's last earnings report?
  • When does Akari Therapeutics report earnings?
  • Should I buy Akari Therapeutics stock now?

What is the ticker symbol for Akari Therapeutics?

The ticker symbol for Akari Therapeutics is NASDAQ:AKTX

Does Akari Therapeutics pay dividends?

No, Akari Therapeutics does not pay dividends

What sector is Akari Therapeutics in?

Akari Therapeutics is in the Healthcare sector

What industry is Akari Therapeutics in?

Akari Therapeutics is in the Biotechnology industry

What country is Akari Therapeutics based in?

Akari Therapeutics is headquartered in United States

When did Akari Therapeutics go public?

Akari Therapeutics's initial public offering (IPO) was on January 6, 2014

Is Akari Therapeutics in the S&P 500?

No, Akari Therapeutics is not included in the S&P 500 index

Is Akari Therapeutics in the NASDAQ 100?

No, Akari Therapeutics is not included in the NASDAQ 100 index

Is Akari Therapeutics in the Dow Jones?

No, Akari Therapeutics is not included in the Dow Jones index

When was Akari Therapeutics's last earnings report?

Akari Therapeutics's most recent earnings report was on Aug 19, 2024

When does Akari Therapeutics report earnings?

The next expected earnings date for Akari Therapeutics is Apr 1, 2025

Should I buy Akari Therapeutics stock now?

As of today, analysts generally recommend a 'Buy' rating. However, it's important to do your own research and consider your financial situation before making any investment decisions